1
|
Oka Y, Abe-Sato K, Tabuse H, Yasukawa Y, Yahara T, Nishimoto T, Kamitani M, Fukunaga T, Ochiai N, Kumasaka-Abe T, Hitaka K, Gunji E, Ohara H, Takeda T, Kojima N, Asami T. Discovery of TP0628103: A Highly Potent and Selective MMP-7 Inhibitor with Reduced OATP-Mediated Clearance Designed by Shifting Isoelectric Points. J Med Chem 2024; 67:1406-1420. [PMID: 38214909 DOI: 10.1021/acs.jmedchem.3c01967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2024]
Abstract
Matrix metalloproteinase-7 (MMP-7) has been shown to play an important role in pathophysiological processes such as cancer and fibrosis. We previously discovered selective MMP-7 inhibitors by molecular hybridization and structure-based drug design. However, the systemic clearance (CLtot) of the biologically active lead compound was very high. Because our studies revealed that hepatic uptake by organic anion transporting polypeptide (OATP) was responsible for the high CLtot, we found a novel approach to reducing their uptake based on isoelectric point (IP) values as an indicator for substrate recognition by OATP1B1/1B3. Our "IP shift strategy" to adjust the IP values culminated in the discovery of TP0628103 (18), which is characterized by reduced in vitro OATP-mediated hepatic uptake and in vivo CLtot. Our in vitro-in vivo extrapolation of OATP-mediated clearance and the "IP shift strategy" provide crucial insights for a new medicinal chemistry approach to reducing the systemic clearance of OATP1B1/1B3 substrates.
Collapse
Affiliation(s)
- Yusuke Oka
- Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Kumi Abe-Sato
- Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Hideaki Tabuse
- Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Yoshifumi Yasukawa
- Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Tohru Yahara
- Drug Metabolism and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Tomohiro Nishimoto
- Drug Metabolism and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Masafumi Kamitani
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Takuya Fukunaga
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Nagahiro Ochiai
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Tomoko Kumasaka-Abe
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Kosuke Hitaka
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Emi Gunji
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Hiroki Ohara
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Takuya Takeda
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Naoki Kojima
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Taiji Asami
- Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| |
Collapse
|
2
|
Park KC, Dharmasivam M, Richardson DR. The Role of Extracellular Proteases in Tumor Progression and the Development of Innovative Metal Ion Chelators that Inhibit their Activity. Int J Mol Sci 2020; 21:E6805. [PMID: 32948029 PMCID: PMC7555822 DOI: 10.3390/ijms21186805] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2020] [Revised: 09/11/2020] [Accepted: 09/14/2020] [Indexed: 12/21/2022] Open
Abstract
The crucial role of extracellular proteases in cancer progression is well-known, especially in relation to the promotion of cell invasion through extracellular matrix remodeling. This also occurs by the ability of extracellular proteases to induce the shedding of transmembrane proteins at the plasma membrane surface or within extracellular vesicles. This process results in the regulation of key signaling pathways by the modulation of kinases, e.g., the epidermal growth factor receptor (EGFR). Considering their regulatory roles in cancer, therapeutics targeting various extracellular proteases have been discovered. These include the metal-binding agents di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) and di-2-pyridylketone-4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), which increase c-MET degradation by multiple mechanisms. Both the direct and indirect inhibition of protease expression and activity can be achieved through metal ion depletion. Considering direct mechanisms, chelators can bind zinc(II) that plays a catalytic role in enzyme activity. In terms of indirect mechanisms, Dp44mT and DpC potently suppress the expression of the kallikrein-related peptidase-a prostate-specific antigen-in prostate cancer cells. The mechanism of this activity involves promotion of the degradation of the androgen receptor. Additional suppressive mechanisms of Dp44mT and DpC on matrix metalloproteases (MMPs) relate to their ability to up-regulate the metastasis suppressors N-myc downstream regulated gene-1 (NDRG1) and NDRG2, which down-regulate MMPs that are crucial for cancer cell invasion.
Collapse
Affiliation(s)
- Kyung Chan Park
- Molecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, Medical Foundation Building, University of Sydney, Sydney 2006, Australia; (K.C.P.); (M.D.)
| | - Mahendiran Dharmasivam
- Molecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, Medical Foundation Building, University of Sydney, Sydney 2006, Australia; (K.C.P.); (M.D.)
- Centre for Cancer Cell Biology and Drug Discovery, Griffith Institute of Drug Discovery, Griffith University, Nathan, Brisbane 4111, Australia
| | - Des R. Richardson
- Molecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, Medical Foundation Building, University of Sydney, Sydney 2006, Australia; (K.C.P.); (M.D.)
- Centre for Cancer Cell Biology and Drug Discovery, Griffith Institute of Drug Discovery, Griffith University, Nathan, Brisbane 4111, Australia
- Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
| |
Collapse
|
3
|
Hariono M, Nuwarda RF, Yusuf M, Rollando R, Jenie RI, Al-Najjar B, Julianus J, Putra KC, Nugroho ES, Wisnumurti YK, Dewa SP, Jati BW, Tiara R, Ramadani RD, Qodria L, Wahab HA. Arylamide as Potential Selective Inhibitor for Matrix Metalloproteinase 9 (MMP9): Design, Synthesis, Biological Evaluation, and Molecular Modeling. J Chem Inf Model 2019; 60:349-359. [PMID: 31825614 DOI: 10.1021/acs.jcim.9b00630] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Previous studies have reported that compounds bearing an arylamide linked to a heterocyclic planar ring have successfully inhibited the hemopexin-like domain (PEX9) of matrix metalloproteinase 9 (MMP9). PEX9 has been suggested to be more selectively targeted than MMP9's catalytic domain in a degrading extracellular matrix under some pathologic conditions, especially in cancer. In this study, we aim to synthesize and evaluate 10 arylamide compounds as MMP9 inhibitors through an enzymatic assay as well as a cellular assay. The mechanism of inhibition for the most active compounds was investigated via molecular dynamics simulation (MD). Molecular docking was performed using AutoDock4.0 with PEX9 as the protein model to predict the binding of the designed compounds. The synthesis was carried out by reacting aniline derivatives with 3-bromopropanoyl chloride using pyridine as the catalyst at room temperature. The MMP9 assay was conducted using the FRET-based MMP9 kits protocol and gelatin zymography assay. The cytotoxicity assay was done using the MTT method, and the MD simulation was performed using AMBER16. Assay on MMP9 demonstrated activities of three compounds (2, 7, and 9) with more than 50% inhibition. Further inhibition on MMP9 expressed by 4T1 showed that two compounds (7 and 9) inhibited its gelatinolytic activity more than 50%. The cytotoxicity assay against 4T1 cells results in the inhibition of the cell growth with an EC50 of 125 μM and 132 μM for 7 and 9, respectively. The MD simulation explained a stable interaction of 7 and 9 in PEX9 at 100 ns with a free energy of binding of -8.03 kcal/mol and -6.41 kcal/mol, respectively. Arylamides have potential effects as selective MMP9 inhibitors in inhibiting breast cancer cell progression.
Collapse
Affiliation(s)
- Maywan Hariono
- Faculty of Pharmacy , Sanata Dharma University , Depok, Sleman 55282 , Yogyakarta , Indonesia
| | - Rina F Nuwarda
- Faculty of Pharmacy , Padjadjaran University , Jatinangor, Sumedang 45363 , West Java , Indonesia
| | - Muhammad Yusuf
- Chemistry Department, Faculty of Mathematics and Natural Sciences , Padjadjaran University , Jatinangor, Sumedang 45363 , West Java , Indonesia
| | - Rollando Rollando
- Pharmacy Program, Faculty of Science and Technology , Ma Chung University , Malang 65151 , Indonesia
| | - Riris I Jenie
- Cancer Chemoprevention Research Center, Faculty of Pharmacy , Gadjah Mada University , Sekip Utara 55281 , Yogyakarta , Indonesia
| | - Belal Al-Najjar
- Faculty of Pharmacy and Medical Sciences , AlAhliyya Amman University , Amman 19328 , Jordan
| | - Jeffry Julianus
- Faculty of Pharmacy , Sanata Dharma University , Depok, Sleman 55282 , Yogyakarta , Indonesia
| | - Kevin C Putra
- Faculty of Pharmacy , Sanata Dharma University , Depok, Sleman 55282 , Yogyakarta , Indonesia
| | - Ervan S Nugroho
- Faculty of Pharmacy , Sanata Dharma University , Depok, Sleman 55282 , Yogyakarta , Indonesia
| | - Yohanes K Wisnumurti
- Faculty of Pharmacy , Sanata Dharma University , Depok, Sleman 55282 , Yogyakarta , Indonesia
| | - Sangga P Dewa
- Faculty of Pharmacy , Sanata Dharma University , Depok, Sleman 55282 , Yogyakarta , Indonesia
| | - Benedictus W Jati
- Faculty of Pharmacy , Sanata Dharma University , Depok, Sleman 55282 , Yogyakarta , Indonesia
| | - Reynaldo Tiara
- Faculty of Pharmacy , Sanata Dharma University , Depok, Sleman 55282 , Yogyakarta , Indonesia
| | - Ratna D Ramadani
- Cancer Chemoprevention Research Center, Faculty of Pharmacy , Gadjah Mada University , Sekip Utara 55281 , Yogyakarta , Indonesia
| | - Lailatul Qodria
- Cancer Chemoprevention Research Center, Faculty of Pharmacy , Gadjah Mada University , Sekip Utara 55281 , Yogyakarta , Indonesia
| | - Habibah A Wahab
- Pharmaceutical Technology Department, School of Pharmaceutical Sciences and USM-RIKEN Centre for Ageing Science (URICAS) , Universiti Sains Malaysia , 11800 Minden , Pulau Pinang , Malaysia
| |
Collapse
|
4
|
Hariono M, Yuliani SH, Istyastono EP, Riswanto FD, Adhipandito CF. Matrix metalloproteinase 9 (MMP9) in wound healing of diabetic foot ulcer: Molecular target and structure-based drug design. ACTA ACUST UNITED AC 2018. [DOI: 10.1016/j.wndm.2018.05.003] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
5
|
Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders. PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE 2017; 148:355-420. [PMID: 28662828 DOI: 10.1016/bs.pmbts.2017.04.003] [Citation(s) in RCA: 86] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Matrix metalloproteinases (MMPs) are zinc-dependent proteolytic enzymes that degrade various proteins in the extracellular matrix (ECM). MMPs may also regulate the activity of membrane receptors and postreceptor signaling mechanisms and thereby affect cell function. The MMP family includes collagenases, gelatinases, stromelysins, matrilysins, membrane-type MMPs, and other MMPs. Inactive proMMPs are cleaved by other MMPs or proteases into active MMPs, which interact with various protein substrates in ECM and cell surface. MMPs regulate important biological processes such as vascular remodeling and angiogenesis and may be involved in the pathogenesis of cardiovascular disorders such as hypertension, atherosclerosis, and aneurysm. The role of MMPs is often assessed by measuring their mRNA expression, protein levels, and proteolytic activity using gel zymography. MMP inhibitors are also used to assess the role of MMPs in different biological processes and pathological conditions. MMP activity is regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs), and the MMP/TIMP balance could determine the net MMP activity, ECM turnover, and tissue remodeling. Also, several synthetic MMP inhibitors have been developed. Synthetic MMP inhibitors include a large number of zinc-binding globulins (ZBGs), in addition to non-ZBGs and mechanism-based inhibitors. MMP inhibitors have been proposed as potential tools in the management of osteoarthritis, cancer, and cardiovascular disorders. However, most MMP inhibitors have broad-spectrum actions on multiple MMPs and could cause undesirable musculoskeletal side effects. Currently, doxycycline is the only MMP inhibitor approved by the Food and Drug Administration. New generation biological and synthetic MMP inhibitors may show greater MMP specificity and fewer side effects and could be useful in targeting specific MMPs, reducing unrestrained tissue remodeling, and the management of MMP-related pathological disorders.
Collapse
|
6
|
Yu J, Haldar M, Mallik S, Srivastava DK. Role of the Substrate Specificity-Defining Residues of Human SIRT5 in Modulating the Structural Stability and Inhibitory Features of the Enzyme. PLoS One 2016; 11:e0152467. [PMID: 27023330 PMCID: PMC4811591 DOI: 10.1371/journal.pone.0152467] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2015] [Accepted: 03/15/2016] [Indexed: 11/18/2022] Open
Abstract
Sirtuins are emerging as the key regulators of metabolism and aging, and their potential activators and inhibitors are being explored as therapeutics for improving health and treating associated diseases. Despite the global structural similarity among all seven isoforms of sirtuins (of which most of them catalyze the deacetylation reaction), SIRT5 is the only isoform that catalyzes the cleavage of negatively charged acylated substrates, and the latter feature appears to be encoded by the presence of Tyr102 and Arg105 residues at the active site pocket of the enzyme. To determine the contributions of the above residues in SIRT5 (vis a vis the corresponding residues of SIRT1) on substrate selectivity, inhibition by EX527 and nicotinamide, secondary structural features and thermal stability of the enzymes, we created single and double mutations (viz. Y102A, R105l, and Y102A/R105I) in SIRT5. The kinetic data revealed that while Y102A mutant enzyme catalyzed both deacetylation and desuccinylation reactions with comparable efficiencies, R105I and Y102A/R105I mutant enzymes favored the deacetylase reaction. Like SIRT1, the nicotinamide inhibition of SIRT5 double mutant (Y102A/R105I) exhibited the mixed non-competitive behavior. On the other hand, the desuccinylation reaction of both wild-type and Y102A mutant enzymes conformed to the competitive inhibition model. The inhibitory potency of EX527 progressively increased from Y102A, R105I, to Y102A/R105 mutant enzymes in SIRT5, but it did not reach to the level obtained with SIRT1. The CD spectroscopic data for the wild-type and mutant enzymes revealed changes in the secondary structural features of the enzymes, and such changes were more pronounced on examining their thermal denaturation patterns. A cumulative account of our experimental data reveal mutual cooperation between Y102 and R105 residues in promoting the desuccinylation versus deacetylation reaction in SIRT5, and the overall catalytic feature of the enzyme is manifested via the mutation induced modulation in the protein structure.
Collapse
Affiliation(s)
- Junru Yu
- Department of Chemistry and Biochemistry, North Dakota State University, Fargo, North Dakota, United States
| | - Manas Haldar
- Department of Pharmaceutical Sciences, North Dakota State University, Fargo, North Dakota, United States
| | - Sanku Mallik
- Department of Pharmaceutical Sciences, North Dakota State University, Fargo, North Dakota, United States
| | - D. K. Srivastava
- Department of Chemistry and Biochemistry, North Dakota State University, Fargo, North Dakota, United States
- * E-mail:
| |
Collapse
|
7
|
Nuti E, Cantelmo AR, Gallo C, Bruno A, Bassani B, Camodeca C, Tuccinardi T, Vera L, Orlandini E, Nencetti S, Stura EA, Martinelli A, Dive V, Albini A, Rossello A. N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity. J Med Chem 2015; 58:7224-40. [DOI: 10.1021/acs.jmedchem.5b00367] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
- Elisa Nuti
- Dipartimento
di Farmacia, Università di Pisa, via Bonanno 6, 56126 Pisa, Italy
| | - Anna Rita Cantelmo
- Science
and Technological Park, IRCCS MultiMedica, via Fantoli 16/15, 20138 Milan, Italy
| | - Cristina Gallo
- Laboratory
of Translational Research, IRCCS Arcispedale Santa Maria Nuova, viale
Risorgimento 80, 42121 Reggio Emilia, Italy
| | - Antonino Bruno
- Science
and Technological Park, IRCCS MultiMedica, via Fantoli 16/15, 20138 Milan, Italy
| | - Barbara Bassani
- Science
and Technological Park, IRCCS MultiMedica, via Fantoli 16/15, 20138 Milan, Italy
| | - Caterina Camodeca
- Division
of Immunology, Transplants and Infectious Diseases, IRCCS San Raffaele, via Olgettina 60, 20132 Milano, Italy
| | - Tiziano Tuccinardi
- Dipartimento
di Farmacia, Università di Pisa, via Bonanno 6, 56126 Pisa, Italy
| | - Laura Vera
- CEA,
iBiTec-S, Service d’Ingenierie Moleculaire des Proteines (SIMOPRO), CE-Saclay 91191 Gif sur Yvette Cedex, France
| | | | - Susanna Nencetti
- Dipartimento
di Farmacia, Università di Pisa, via Bonanno 6, 56126 Pisa, Italy
| | - Enrico A. Stura
- CEA,
iBiTec-S, Service d’Ingenierie Moleculaire des Proteines (SIMOPRO), CE-Saclay 91191 Gif sur Yvette Cedex, France
| | - Adriano Martinelli
- Dipartimento
di Farmacia, Università di Pisa, via Bonanno 6, 56126 Pisa, Italy
| | - Vincent Dive
- CEA,
iBiTec-S, Service d’Ingenierie Moleculaire des Proteines (SIMOPRO), CE-Saclay 91191 Gif sur Yvette Cedex, France
| | - Adriana Albini
- Laboratory
of Translational Research, IRCCS Arcispedale Santa Maria Nuova, viale
Risorgimento 80, 42121 Reggio Emilia, Italy
| | - Armando Rossello
- Dipartimento
di Farmacia, Università di Pisa, via Bonanno 6, 56126 Pisa, Italy
| |
Collapse
|
8
|
Li MH, Zhang YF, Tian HR, Zheng MH, Yang MY, Fang HL, Xie YZ, Jin JY. Nitro-based selective inhibitors against matrix metalloproteinase-7 over matrix metalloproteinase-1. RSC Adv 2015. [DOI: 10.1039/c5ra22271k] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A series of nitro-based dipeptidic compounds were synthesized and evaluated as matrix metalloproteinase (MMP) inhibitors, with improved selectivity for the inhibition of MMP-7 over MMP-1.
Collapse
Affiliation(s)
- Mei-Hua Li
- Department of Chemistry
- College of Science
- Yanbian University
- Yanji City
- China
| | - Yan-Feng Zhang
- Department of Chemistry
- College of Science
- Yanbian University
- Yanji City
- China
| | - Hong-Rui Tian
- Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules
- Ministry of Education
- Yanbian University
- Yanji City
- China
| | - Ming-Hua Zheng
- Department of Chemistry
- College of Science
- Yanbian University
- Yanji City
- China
| | - Ming-Yang Yang
- Department of Chemistry
- College of Science
- Yanbian University
- Yanji City
- China
| | - Hu-Lin Fang
- Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules
- Ministry of Education
- Yanbian University
- Yanji City
- China
| | - Yu-Zhong Xie
- Department of Chemistry
- College of Science
- Yanbian University
- Yanji City
- China
| | - Jing-Yi Jin
- Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules
- Ministry of Education
- Yanbian University
- Yanji City
- China
| |
Collapse
|
9
|
Mori M, Massaro A, Calderone V, Fragai M, Luchinat C, Mordini A. Discovery of a New Class of Potent MMP Inhibitors by Structure-Based Optimization of the Arylsulfonamide Scaffold. ACS Med Chem Lett 2013; 4:565-9. [PMID: 24900710 DOI: 10.1021/ml300446a] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2012] [Accepted: 03/13/2013] [Indexed: 01/29/2023] Open
Abstract
A new class of potent matrix metalloproteinase (MMP) inhibitors designed by structure-based optimization of the well-known arylsulfonamide scaffold is presented. Molecules show an ethylene linker connecting the sulfonamide group with the P1' aromatic portion and a d-proline residue bearing the zinc-binding group. The affinity improvement provided by these modifications led us to discover a nanomolar MMP inhibitor bearing a carboxylate moiety as zinc-binding group, which might be a promising lead molecule. Notably, a significant selectivity for MMP-8, MMP-12, and MMP-13 was observed with respect to MMP-1 and MMP-7.
Collapse
Affiliation(s)
- Mattia Mori
- ProtEra Srl, Scientific Campus, University of Florence, viale delle idee 22, I-50019
Sesto Fiorentino, Italy
- Magnetic Resonance Center (CERM), University of Florence, via L. Sacconi 6, I-50019 Sesto
Fiorentino, Italy
| | - Assunta Massaro
- ProtEra Srl, Scientific Campus, University of Florence, viale delle idee 22, I-50019
Sesto Fiorentino, Italy
| | - Vito Calderone
- Magnetic Resonance Center (CERM), University of Florence, via L. Sacconi 6, I-50019 Sesto
Fiorentino, Italy
| | - Marco Fragai
- Magnetic Resonance Center (CERM), University of Florence, via L. Sacconi 6, I-50019 Sesto
Fiorentino, Italy
- Department
of Chemistry “Ugo
Shiff”, University of Florence,
via della Lastruccia 3, I-50019 Sesto Fiorentino, Italy
| | - Claudio Luchinat
- Magnetic Resonance Center (CERM), University of Florence, via L. Sacconi 6, I-50019 Sesto
Fiorentino, Italy
- Department
of Chemistry “Ugo
Shiff”, University of Florence,
via della Lastruccia 3, I-50019 Sesto Fiorentino, Italy
| | - Alessandro Mordini
- ICCOM-CNR, Dipartimento
di Chimica “U. Schiff”, via della Lastruccia
13, I-50019 Sesto Fiorentino, Italy
| |
Collapse
|
10
|
Kucukguven A, Khalil RA. Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins. Curr Drug Targets 2013; 14:287-324. [PMID: 23316963 PMCID: PMC3584231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2012] [Revised: 11/20/2012] [Accepted: 01/01/2012] [Indexed: 06/01/2023]
Abstract
Varicose veins (VVs) are a common venous disease of the lower extremity characterized by incompetent valves, venous reflux, and dilated and tortuous veins. If untreated, VVs could lead to venous thrombosis, thrombophlebitis and chronic venous leg ulcers. Various genetic, hormonal and environmental factors may lead to structural changes in the vein valves and make them incompetent, leading to venous reflux, increased venous pressure and vein wall dilation. Prolonged increases in venous pressure and vein wall tension are thought to increase the expression/activity of matrix metalloproteinases (MMPs). Members of the MMPs family include collagenases, gelatinases, stromelysins, matrilysins, membrane- type MMPs and others. MMPs are known to degrade various components of the extracellular matrix (ECM). MMPs may also affect the endothelium and vascular smooth muscle, causing changes in the vein relaxation and contraction mechanisms. Endothelial cell injury also triggers leukocyte infiltration, activation and inflammation, which lead to further vein wall damage. The vein wall dilation and valve dysfunction, and the MMP activation and superimposed inflammation and fibrosis would lead to progressive venous dilation and VVs formation. Surgical ablation is an effective treatment for VVs, but may be associated with high recurrence rate, and other less invasive approaches that target the cause of the disease are needed. MMP inhibitors including endogenous tissue inhibitors (TIMPs) and pharmacological inhibitors such as zinc chelators, doxycycline, batimastat and marimastat, have been used as diagnostic and therapeutic tools in cancer, autoimmune and cardiovascular disease. However, MMP inhibitors may have side effects especially on the musculoskeletal system. With the advent of new genetic and pharmacological tools, specific MMP inhibitors with fewer undesirable effects could be useful to retard the progression and prevent the recurrence of VVs.
Collapse
Affiliation(s)
- Arda Kucukguven
- Vascular Surgery Research Laboratory, Division of Vascular and Endovascular Surgery, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA 02115, USA
| | | |
Collapse
|
11
|
Hydroxamic Acids as Matrix Metalloproteinase Inhibitors. MATRIX METALLOPROTEINASE INHIBITORS 2012; 103:137-76. [DOI: 10.1007/978-3-0348-0364-9_5] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
|
12
|
Patil VM, Gupta SP. Quantitative structure-activity relationship studies on sulfonamide-based MMP inhibitors. EXPERIENTIA SUPPLEMENTUM (2012) 2012; 103:177-208. [PMID: 22642193 DOI: 10.1007/978-3-0348-0364-9_6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Matrix metalloproteinases (MMPs) regulate a wide range of biological functions, but their overactivation leads to a wide array of disease processes such as rheumatoid arthritis, ostereoarthritis, tumor metastatis, multiple sclerosis, congestive heart failure, and a host of others. Therefore, the study of MMP inhibitors has evoked a great interest among scientists. As a result, different groups of compounds have been synthesized and studied for MMP inhibitions. Among them, a large number of structurally novel sulfonamide derivatives have been reported to be potential MMP inhibitors, but only a few have reached to the final stage of clinical trial. Many authors have made quantitative structure-activity relationship (QSAR) studies on them to provide the guidelines to design more potent MMP inhibitors. This article presents a comprehensive review on all such QSARs reported with critical assessment in order to provide a deeper insight into the structure-activity relationship of sulfonamides which can be used to synthesize highly potential drugs of pharmaceutical importance.
Collapse
Affiliation(s)
- Vaishali M Patil
- School of Pharmacy, Bharat Institute of Technology, Meerut 250103, India.
| | | |
Collapse
|
13
|
Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. EXPERIENTIA SUPPLEMENTUM (2012) 2012; 103:209-79. [PMID: 22642194 DOI: 10.1007/978-3-0348-0364-9_7] [Citation(s) in RCA: 85] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Matrix metalloproteinases (MMPs) are proteolytic enzymes that degrade various components of the extracellular matrix (ECM). MMPs could also regulate the activity of several non-ECM bioactive substrates and consequently affect different cellular functions. Members of the MMPs family include collagenases, gelatinases, stromelysins, matrilysins, membrane-type MMPs, and others. Pro-MMPs are cleaved into active MMPs, which in turn act on various substrates in the ECM and on the cell surface. MMPs play an important role in the regulation of numerous physiological processes including vascular remodeling and angiogenesis. MMPs may also be involved in vascular diseases such as hypertension, atherosclerosis, aortic aneurysm, and varicose veins. MMPs also play a role in the hemodynamic and vascular changes associated with pregnancy and preeclampsia. The role of MMPs is commonly assessed by measuring their gene expression, protein amount, and proteolytic activity using gel zymography. Because there are no specific activators of MMPs, MMP inhibitors are often used to investigate the role of MMPs in different physiologic processes and in the pathogenesis of specific diseases. MMP inhibitors include endogenous tissue inhibitors (TIMPs) and pharmacological inhibitors such as zinc chelators, doxycycline, and marimastat. MMP inhibitors have been evaluated as diagnostic and therapeutic tools in cancer, autoimmune disease, and cardiovascular disease. Although several MMP inhibitors have been synthesized and tested both experimentally and clinically, only one MMP inhibitor, i.e., doxycycline, is currently approved by the Food and Drug Administration. This is mainly due to the undesirable side effects of MMP inhibitors especially on the musculoskeletal system. While most experimental and clinical trials of MMP inhibitors have not demonstrated significant benefits, some trials still showed promising results. With the advent of new genetic and pharmacological tools, disease-specific MMP inhibitors with fewer undesirable effects are being developed and could be useful in the management of vascular disease.
Collapse
|
14
|
Viso A, Fernández de la Pradilla R, Tortosa M, García A, Flores A. Update 1 of: α,β-Diamino Acids: Biological Significance and Synthetic Approaches. Chem Rev 2011; 111:PR1-42. [DOI: 10.1021/cr100127y] [Citation(s) in RCA: 85] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Affiliation(s)
- Alma Viso
- Instituto de Química Orgánica, CSIC, Juan de la Cierva 3, E-28006 Madrid, Spain
| | | | - Mariola Tortosa
- Instituto de Química Orgánica, CSIC, Juan de la Cierva 3, E-28006 Madrid, Spain
| | - Ana García
- Instituto de Química Orgánica, CSIC, Juan de la Cierva 3, E-28006 Madrid, Spain
| | - Aida Flores
- Instituto de Química Orgánica, CSIC, Juan de la Cierva 3, E-28006 Madrid, Spain
| |
Collapse
|
15
|
To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH 2009; 1803:72-94. [PMID: 19712708 DOI: 10.1016/j.bbamcr.2009.08.006] [Citation(s) in RCA: 219] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/27/2009] [Revised: 08/12/2009] [Accepted: 08/12/2009] [Indexed: 12/14/2022]
Abstract
This short review highlights some recent advances in matrix metalloproteinase inhibitor (MMPi) design and development. Three distinct approaches to improved MMP inhibition are discussed: (1) the identification and investigation of novel zinc-binding groups (ZBGs), (2) the study of non-zinc-binding MMPi, and (3) mechanism-based MMPi that form covalent adducts with the protein. Each of these strategies is discussed and their respective advantages and remaining challenges are highlighted. The studies discussed here bode well for the development of ever more selective, potent, and well-tolerated MMPi for treating several important disease pathologies.
Collapse
|